VAB-3 combination chemotherapy of metastatic testicular cancer
作者： Thomas F. Reynolds , Davor Vugrin , Esteban Cvitkovic , Edgar Cheng , David W. Braun
DOI: 10.1002/1097-0142(19810815)48:4<888::AID-CNCR2820480405>3.0.CO;2-D
关键词: Vinblastine 、 Performance status 、 Testicular cancer 、 Oncology 、 Internal medicine 、 Gastroenterology 、 Medicine 、 Chemotherapy 、 Bleomycin 、 Toxicity 、 Histology 、 Combination chemotherapy 、 Cancer research
摘要: The initial response and long-term follow-up of 74 evaluable patients who received combination chemotherapy for metastatic nonseminomatous testicular cancer are reported. Patients were treated with a protocol (VAB-3) including vinblastine, actinomycin-D, bleomycin, cis-dichlorodiammine platinum (DDP). VAB-3 alone caused complete remission (CR) in 54% (40/74) partial (PR) 26% (1974). Five less than CR to achieved following surgical excision residual mature teratoma after starting protocol, resulting an overall rate 61% (45/74). With minimum 24+ months, median 35+ months those still living, 45% (33/74) the living free evidence disease, 4% (3/74) 51% (38/74) dead. Response was examined respect performance status, histology, prior therapy, extent tumor markers, duration disease from diagnosis. No one died because toxicity VAB-3, life-threatening uncommon. Long survival is significantly associated (P 0.001) achievement CR. treatment goal cure. CR, using aggressive surgery, essential reaching this goal.
sci-hub.se 参考文章(31)
Richard Peto, M. C. Pike, Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. ,vol. 29, pp. 579- 584 ,(1973) , 10.2307/2529177
D. L. March, Algorithm 434: exact probabilities for
R×C
contingency tables [G2] Communications of the ACM. ,vol. 15, pp. 991- 992 ,(1972) , 10.1145/355606.355607
David L. March, Exact probabilities for R x C contingency tables [G2] Communications of the ACM. ,vol. 15, pp. 991- 992 ,(1972) , 10.1145/355606.361890
M. ZELEN, The analysis of several 2× 2 contingency tables Biometrika. ,vol. 58, pp. 129- 137 ,(1971) , 10.1093/BIOMET/58.1.129
Esteban Cvitkovic, Joseph Spaulding, Vlctor Bethune, James Martin, Willet F. Whitmore, Improvement of Cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model Cancer. ,vol. 39, pp. 1357- 1361 ,(1977) , 10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Waun Ki Hong, Robert E. Wittes, Steven T. Hajdu, Esteban Cvitkovic, Willet F. Whitmore, Robert B. Golbey, The evolution of mature teratoma from malignant testicular tumors. Cancer. ,vol. 40, pp. 2987- 2992 ,(1977) , 10.1002/1097-0142(197712)40:6<2987::AID-CNCR2820400634>3.0.CO;2-A
Melvin L. Samuels, Paul Y. Holoye, Douglas E. Johnson, Bleomycin combination chemotherapy in the management of testicular neoplasia Cancer. ,vol. 36, pp. 318- 326 ,(1975) , 10.1002/1097-0142(197508)36:2<318::AID-CNCR2820360205>3.0.CO;2-V
Edgar Cheng, Esteban Cvitkovic, Robert E. Wittes, Robert B. Golbey, Germ cell tumors (II). VAB II in metastatic testicular cancer Cancer. ,vol. 42, pp. 2162- 2168 ,(1978) , 10.1002/1097-0142(197811)42:5<2162::AID-CNCR2820420512>3.0.CO;2-I
Claude Merrin, George Baumgartner, Zew Wajsman, BENIGN TRANSFORMATION OF TESTICULAR CARCINOMA BY CHEMOTHERAPY The Lancet. ,vol. 305, pp. 43- 44 ,(1975) , 10.1016/S0140-6736(75)92411-3